AbbVie and Johnson & Johnson receive FDA approval

The chemo-free combination of Imbruvica (a drug split by AbbVie and Johnson & Johnson) and Roche’s Rituxan has received FDA approval for the treatment of the rare blood cancer Waldenström's macroglobulinemia. Investigators recorded a 30-month progression-free survival figure of 82% for patients on the drug combo, compared with 28% for patients on Rituxan alone.

Click here to view the entire article.